ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Announces That the Phase III Study of timdarpacept (IMM01) for CMML Has Completed Enrollment of 133 Subjects, Achieving the Milestone of 132 Subjects for Interim Analysis

ImmuneOnco’s Amouravfop Alfa (IMM0306) Granted NMPA Approval for Phase II Study in Primary Membranous Nephropathy

NMPA Approves ImmuneOnco’s IMM0306S for SLE, Highlighting Robust Autoimmune Pipeline

In parallel, ImmuneOnco has recently submitted an IND application to the NMPA for a subcutaneous formulation of IMM0306, which has been accepted for review. This next-generation delivery method aims to enhance patient convenience and long-term treatment adherence. Combined with prior clinical trial progress or IND submissions across multiple immune-mediated indications—including relapsed/refractory follicular lymphoma (in combination with lenalidomide; Phase III approved), SLE (Phase Ib/II), neuromyelitis optica spectrum disorder (NMOSD; Phase Ib/III), lupus nephritis (LN; Phase II), and primary membranous nephropathy (PMN; IND accepted)—the systematic advancement of IMM0306 in autoimmune diseases underscores the broad therapeutic potential of the CD47×CD20 dual-target mechanism and establishes a solid platform for future expansion into additional autoimmune conditions.

Shanghai, China, 28 January 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,